South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain
On October 12, 2023, South Rampart Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track status to its drug candidate, SRP-001, intended for the management of acute pain. SRP-001 is an innovative, pioneering non-opioid analgesic that activates pain signaling pathways in the periaqueductal grey (PAG) region of the midbrain, free from liver and kidney toxicity concerns.
SRP-001 exerts its influence on pain-related genes by modulating pathways within the PAG region, including the endocannabinoid, mechanical nociception, and fatty a...